Reconstruction of antibody dynamics and infection hist

Nature 557, 719-723 DOI: 10.1038/s41586-018-0157-4

Citation Report

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. Cell Reports, 2018, 25, 1385-1394.e7. | 6.4 | 61 |
| 2 | Risk of Dengue in Travelers: Implications for Dengue Vaccination. Current Infectious Disease Reports, 2018, 20, 50. | 3.0 | 17 |
| 3 | Dengue: a growing threat requiring vaccine development for disease prevention. Pathogens and Global Health, 2018, 112, 294-305. | 2.3 | 32 |
| 4 | Assessment of benefits and risks associated with dengue vaccination at the individual and population levels: a dynamic modeling approach. Expert Review of Vaccines, 2018, 17, 753-763. | 4.4 | 3 |
| 5 | Challenges and opportunities in controlling mosquito-borne infections. Nature, 2018, 559, 490-497. | 27.8 | 111 |
| 6 | Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers. Journal of Travel Medicine, 2018, 25, . | 3.0 | 33 |
| 7 | Severe dengue in travellers: pathogenesis, risk and clinical management. Journal of Travel Medicine, 2019, 26, . | 3.0 | 86 |
| 8 | Risk of Zika microcephaly correlates with features of maternal antibodies. Journal of Experimental Medicine, 2019, 216, 2302-2315. | 8.5 | 41 |
| 9 | A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice. Frontiers in Immunology, 2019, 10, 1424. | 4.8 | 59 |
| 10 | Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus. Frontiers in Cellular and Infection Microbiology, 2019, 9, 200. | 3.9 | 13 |
| 11 | Thermal biology of mosquitoâ€borne disease. Ecology Letters, 2019, 22, 1690-1708. | 6.4 | 349 |
| 12 | Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development. Frontiers in Immunology, 2019, 10, 1316. | 4.8 | 51 |
| 13 | Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam. Scientific Reports, 2019, 9, 9395. | 3.3 | 33 |
| 14 | West Nile Virus and Usutu Virus Co-Circulation in Europe: Epidemiology and Implications. Microorganisms, 2019, 7, 184. | 3.6 | 58 |
| 15 | Longitudinal Analysis of Memory B and T Cell Responses to Dengue Virus in a 5-Year Prospective Cohort Study in Thailand. Frontiers in Immunology, 2019, 10, 1359. | 4.8 | 11 |
| 16 | A review of Dengvaxia®: development to deployment. Human Vaccines and Immunotherapeutics, 2019, 15, 2295-2314. | 3.3 | 206 |
| 17 | Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas. Scientific Reports, 2019, 9, 16258. | 3.3 | 10 |
| 18 | West Nile virus infection in individuals with pre-existing Usutu virus immunity, northern Italy, 2018. Eurosurveillance, 2019, 24, . | 7.0 | 18 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Selective Detection of Dengue Virus Serotypes Using Tandem Toehold-Mediated Displacement Reactions. ACS Infectious Diseases, 2019, 5, 1907-1914. | 3.8 | 10 |
| 20 | Dengue. Lancet, The, 2019, 393, 350-363. | 13.7 | 420 |
| 21 | Influence of chemokines on the endothelial permeability and cellular transmigration during dengue. Immunology Letters, 2019, 212, 88-97. | 2.5 | 5 |
| 22 | Serologic Tools and Strategies to Support Intervention Trials to Combat Zika Virus Infection and Disease. Tropical Medicine and Infectious Disease, 2019, 4, 68. | 2.3 | 11 |
| 23 | Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines. PLoS Pathogens, 2019, 15, e1007721. | 4.7 | 27 |
| 24 | Effects of infection history on dengue virus infection and pathogenicity. Nature Communications, 2019, 10, 1246. | 12.8 | 26 |
| 25 | An antiviral drug screening system for enterovirus 71 based on an improved plaque assay: A potential highâ€ŧhroughput method. Journal of Medical Virology, 2019, 91, 1440-1447. | 5.0 | 12 |
| 26 | Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?. Current Opinion in Immunology, 2019, 59, 1-8. | 5.5 | 37 |
| 27 | Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Neglected Tropical Diseases, 2019, 13, e0007213. | 3.0 | 484 |
| 28 | Recent advances in understanding dengue. F1000Research, 2019, 8, 1279. | 1.6 | 63 |
| 29 | Impaired Antibody-Independent Immune Response of B Cells in Patients With Acute Dengue Infection. Frontiers in Immunology, 2019, 10, 2500. | 4.8 | 12 |
| 30 | The first licensed dengue vaccine. Current Opinion in Infectious Diseases, 2019, 32, 394-400. | 3.1 | 13 |
| 31 | Dengue in hospitalized children with sickle cell disease: A retrospective cohort study in the French departments of America. Journal of Infection and Public Health, 2020, 13, 186-192. | 4.1 | 17 |
| 32 | The Global Expansion of Dengue: How <i>Aedes aegypti</i> Mosquitoes Enabled the First Pandemic Arbovirus. Annual Review of Entomology, 2020, 65, 191-208. | 11.8 | 203 |
| 33 | Zika Virus Infection in Pregnancy: Advanced Diagnostic Approaches in Dengue-Naive and Dengue-Experienced Pregnant Women and Possible Implication for Cross-Reactivity and Cross-Protection. Microorganisms, 2020, 8, 56. | 3.6 | 3 |
| 34 | Re-emergence of dengue virus serotype 3 infections in Gabon in 2016–2017, and evidence for the risk of repeated dengue virus infections. International Journal of Infectious Diseases, 2020, 91, 129-136. | 3.3 | 29 |
| 35 | Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. Current Opinion in Virology, 2020, 43, 59-70. | 5.4 | 41 |
| 36 | Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine. Frontiers in Cellular and Infection Microbiology, 2020, 10, 572681. | 3.9 | 103 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 37 | The role of IgG Fc receptors in antibody-dependent enhancement. Nature Reviews Immunology, 2020, 20, 633-643. | 22.7 | 340 |
| 38 | Japanese encephalitis virus–primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis. Journal of Experimental Medicine, 2020, 217, . | 8.5 | 10 |
| 39 | Fine-scale heterogeneity in <i>Schistosoma mansoni</i> force of infection measured through antibody response. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23174-23181. | 7.1 | 14 |
| 40 | Protection against dengue virus requires a sustained balance of antibody and T cell responses. Current Opinion in Virology, 2020, 43, 22-27. | 5.4 | 3 |
| 41 | Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models. EBioMedicine, 2020, 60, 102991. | 6.1 | 21 |
| 42 | Zika virus infection enhances future risk of severe dengue disease. Science, 2020, 369, 1123-1128. | 12.6 | 171 |
| 43 | Climate change could shift disease burden from malaria to arboviruses in Africa. Lancet Planetary Health, The, 2020, 4, e416-e423. | 11.4 | 163 |
| 44 | A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nature Communications, 2020, 11, 4704. | 12.8 | 775 |
| 45 | Risk of dengue virus infection according to serostatus in individuals from dengue endemic areas of Mexico. Scientific Reports, 2020, 10, 19017. | 3.3 | 6 |
| 46 | Autoantibody Profiling in Plasma of Dengue Virus–Infected Individuals. Pathogens, 2020, 9, 1060. | 2.8 | 6 |
| 47 | Protective Immunity to Dengue Virus Induced by DNA Vaccines Encoding Nonstructural Proteins in a Lethal Challenge Immunocompetent Mouse Model. Frontiers in Medical Technology, 2020, 2, 558984. | 2.5 | 2 |
| 48 | ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. Cytokine, 2020, 136, 155256. | 3.2 | 26 |
| 49 | Hidden heterogeneity and its influence on dengue vaccination impact. Infectious Disease Modelling, 2020, 5, 783-797. | 1.9 | 2 |
| 50 | CD8 ⁺ T cells mediate protection against Zika virus induced by an NS3-based vaccine. Science Advances, 2020, 6, . | 10.3 | 20 |
| 51 | An open source tool to infer epidemiological and immunological dynamics from serological data: serosolver. PLoS Computational Biology, 2020, 16, e1007840. | 3.2 | 13 |
| 52 | The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection. International Journal of Infectious Diseases, 2020, 96, 359-360. | 3.3 | 2 |
| 53 | Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections. Journal of Infectious Diseases, 2020, 221, 1846-1854. | 4.0 | 29 |
| 54 | The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines. Viruses, 2020, 12, 520. | 3.3 | 47 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. Cell Host and Microbe, 2020, 27, 710-724.e7. | 11.0 | 25 |
| 56 | Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort. International Journal of Infectious Diseases, 2020, 95, 167-173. | 3.3 | 20 |
| 57 | Combine dengue vaccines to optimize effectiveness. Vaccine, 2020, 38, 4801-4804. | 3.8 | 6 |
| 58 | Spatiotemporal variability in dengue transmission intensity in Jakarta, Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008102. | 3.0 | 15 |
| 59 | Infection severity across scales in multi-strain immuno-epidemiological Dengue model structured by host antibody level. Journal of Mathematical Biology, 2020, 80, 1803-1843. | 1.9 | 21 |
| 60 | Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue. Journal of Infectious Diseases, 2020, 222, 590-600. | 4.0 | 17 |
| 61 | Using cluster analysis to reconstruct dengue exposure patterns from cross-sectional serological studies in Singapore. Parasites and Vectors, 2020, 13, 32. | 2.5 | 8 |
| 62 | Towards Predicting Progression to Severe Dengue. Trends in Microbiology, 2020, 28, 478-486. | 7.7 | 10 |
| 63 | An Innovative, Prospective, Hybrid Cohort-Cluster Study Design to Characterize Dengue Virus Transmission in Multigenerational Households in Kamphaeng Phet, Thailand. American Journal of Epidemiology, 2020, 189, 648-659. | 3.4 | 12 |
| 64 | Mapping global variation in dengue transmission intensity. Science Translational Medicine, 2020, 12, . | 12.4 | 131 |
| 65 | CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. Cell Reports, 2020, 31, 107566. | 6.4 | 31 |
| 66 | A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7981-7989. | 7.1 | 24 |
| 67 | When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?. Vaccines, 2020, 8, 174. | 4.4 | 3 |
| 68 | The â€`lifecycle' of human beings: a call to explore vector-borne diseases from an ecosystem perspective. Infectious Diseases of Poverty, 2020, 9, 37. | 3.7 | 2 |
| 69 | CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals. Clinical Infectious Diseases, 2021, 72, 1730-1737. | 5.8 | 5 |
| 70 | Developments in statistical inference when assessing spatiotemporal disease clustering with the tau statistic. Spatial Statistics, 2021, 42, 100438. | 1.9 | 3 |
| 71 | Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 2021, 19, 211-219. | 28.6 | 126 |
| 72 | Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes. Journal of Virology, 2021, 95, . | 3.4 | 6 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Evolution and epidemiologic dynamics of dengue virus in Nicaragua during the emergence of chikungunya and Zika viruses. Infection, Genetics and Evolution, 2021, 92, 104680. | 2.3 | 6 |
| 76 | Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Reports, 2021, 34, 108699. | 6.4 | 110 |
| 77 | Direct Infection of B Cells by Dengue Virus Modulates B Cell Responses in a Cambodian Pediatric Cohort. Frontiers in Immunology, 2020, 11, 594813. | 4.8 | 14 |
| 78 | Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine, 2021, 32, 100734. | 7.1 | 134 |
| 79 | Surveillance of the major pathogenic arboviruses of public health concern in Gabon, Central Africa: increased risk of West Nile virus and dengue virus infections. BMC Infectious Diseases, 2021, 21, 265. | 2.9 | 21 |
| 80 | Climatic and socio-economic factors supporting the co-circulation of dengue, Zika and chikungunya in three different ecosystems in Colombia. PLoS Neglected Tropical Diseases, 2021, 15, e0009259. | 3.0 | 28 |
| 81 | Boosting can explain patterns of fluctuations of ratios of inapparent to symptomatic dengue virus infections. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 7.1 | 8 |
| 82 | Risk Assessment of Dengue Transmission in Bangladesh Using a Spatiotemporal Network Model and Climate Data. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1444-1455. | 1.4 | 12 |
| 83 | Epidemiology of dengue virus infections in Nepal, 2006–2019. Infectious Diseases of Poverty, 2021, 10, 52. | 3.7 | 31 |
| 84 | Successful management of dengue in renal transplant recipients: A retrospective cohort from a single center. Clinical Transplantation, 2021, 35, e14332. | 1.6 | 1 |
| 85 | Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1729-1733. | 1.4 | 3 |
| 86 | Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?. Frontiers in Immunology, 2021, 12, 673699. | 4.8 | 16 |
| 87 | Correlation between reported dengue illness history and seropositivity in rural Thailand. PLoS Neglected Tropical Diseases, 2021, 15, e0009459. | 3.0 | 2 |
| 88 | Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. Journal of Infectious Diseases, 2022, 225, 332-340. | 4.0 | 1 |
| 89 | Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection. Nature Medicine, 2021, 27, 1395-1400. | 30.7 | 21 |
| 91 | Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduction and Targeted Therapy, 2021, 6, 233. | 17.1 | 203 |
| 92 | Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. PLoS Pathogens, 2021, 17, e1009673. | 4.7 | 7 |
| 93 | Antibody fucosylation predicts disease severity in secondary dengue infection. Science, 2021, 372, 1102-1105. | 12.6 | 67 |

| | CITATION N | LEPORT | |
|---------|---|------------|------------------|
| # 94 | ARTICLE Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science, 2021, 373, . | IF 12.6 | Citations 148 |
| 95 | Spatial Distribution and Burden of Emerging Arboviruses in French Guiana. Viruses, 2021, 13, 1299. | 3.3 | 9 |
| 96 | Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data. ELife, 2021, 10, . | 6.0 | 5 |
| 97 | Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. Lancet Infectious Diseases, The, 2022, 22, e42-e51. | 9.1 | 20 |
| 99 | Previous exposure to dengue virus is associated with increased Zika virus burden at the maternal-fetal interface in rhesus macaques. PLoS Neglected Tropical Diseases, 2021, 15, e0009641. | 3.0 | 20 |
| 100 | Longitudinal Analysis of Dengue Virus–Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection. Frontiers in Immunology, 2021, 12, 710300. | 4.8 | 3 |
| 101 | Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. Frontiers in Immunology, 2021, 12, 703887. | 4.8 | 9 |
| 102 | Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections. Frontiers in Immunology, 2021, 12, 696755. | 4.8 | 4 |
| 105 | Considerations for the 2030 Sustainable Development Goals for dengue. Gates Open Research, 0, 3, 1656. | 1.1 | 3 |
| 106 | Decreased Type I Interferon Production by Plasmacytoid Dendritic Cells Contributes to Severe Dengue. Frontiers in Immunology, 2020, 11, 605087. | 4.8 | 11 |
| 107 | Reemergence of dengue virus in Bangladesh: Current fatality and the required knowledge. Tzu Chi Medical Journal, 2020, 32, 227. | 1.1 | 3 |
| 108 | Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. American Journal of Tropical Medicine and Hygiene, 2019, 101, 164-179. | 1.4 | 9 |
| 109 | Dengue genetic divergence generates within-serotype antigenic variation, but serotypes dominate evolutionary dynamics. ELife, 2019, 8, . | 6.0 | 38 |
| 110 | Nationally-representative serostudy of dengue in Bangladesh allows generalizable disease burden estimates. ELife, 2019, 8, . | 6.0 | 58 |
| 111 | Enteropathogen antibody dynamics and force of infection among children in low-resource settings. ELife, 2019, 8, . | 6.0 | 26 |
| 112 | Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics. ELife, 2019, 8, . | 6.0 | 44 |
| 113 | How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Viruses, 2021, 13, 2106. | 3.3 | 7 |
| 114 | Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. Science Translational Medicine, 2021, 13, eabg9478. | 12.4 | 32 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 116 | Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV). Bioorganic and Medicinal Chemistry Letters, 2021, 52, 128407. | 2.2 | 13 |
| 123 | Effects of Accounting for Interval-Censored Antibody Titer Decay on Seroincidence in a Longitudinal Cohort Study of Leptospirosis. American Journal of Epidemiology, 2021, 190, 893-899. | 3.4 | 1 |
| 126 | A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data. Npj Vaccines, 2021, 6, 133. | 6.0 | 2 |
| 128 | Cross-sectional cycle threshold values reflect epidemic dynamics of COVID-19 in Madagascar. Epidemics, 2022, 38, 100533. | 3.0 | 8 |
| 129 | Antigenic evolution of dengue viruses over 20 years. Science, 2021, 374, 999-1004. | 12.6 | 34 |
| 130 | Model-based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a serological cross-reactivity context. Nature Communications, 2021, 12, 6735. | 12.8 | 4 |
| 131 | The seroepidemiology of dengue in a US military population based in Puerto Rico during the early phase of the Zika pandemic. PLoS Neglected Tropical Diseases, 2022, 16, e0009986. | 3.0 | 1 |
| 132 | Host immunity and vaccine development against Dengue virus. , 2022, , . | | 3 |
| 133 | Reconstructing antibody dynamics to estimate the risk of influenza virus infection. Nature Communications, 2022, 13, 1557. | 12.8 | 9 |
| 134 | Characterising spatial patterns of neglected tropical disease transmission using integrated sero-surveillance in Northern Ghana. PLoS Neglected Tropical Diseases, 2022, 16, e0010227. | 3.0 | 7 |
| 135 | Incorporating temporal distribution of population-level viral load enables real-time estimation of COVID-19 transmission. Nature Communications, 2022, 13, 1155. | 12.8 | 16 |
| 136 | EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil. Trials, 2022, 23, 185. | 1.6 | 5 |
| 137 | Development of Novel Dengue NS1 Multiplex Lateral Flow Immunoassay to Differentiate Serotypes in Serum of Acute Phase Patients and Infected Mosquitoes. Frontiers in Immunology, 2022, 13, 852452. | 4.8 | 9 |
| 140 | A Zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity. Cell Reports, 2022, 39, 110655. | 6.4 | 20 |
| 156 | Innate Immune Response to Dengue Virus: Toll-like Receptors and Antiviral Response. Viruses, 2022, 14, 992. | 3.3 | 12 |
| 157 | Individual, Household, and Community Drivers of Dengue Virus Infection Risk in Kamphaeng Phet Province, Thailand. Journal of Infectious Diseases, 2022, 226, 1348-1356. | 4.0 | 6 |
| 158 | Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand. PLoS Pathogens, 2022, 18, e1010500. | 4.7 | 5 |
| 159 | Assessing the role of multiple mechanisms increasing the age of dengue cases in Thailand. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2115790119. | 7.1 | 16 |

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 160 | Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, . | 4.8 | 4 |
| 161 | Estimating typhoid incidence from community-based serosurveys: a multicohort study. Lancet Microbe, The, 2022, 3, e578-e587. | 7.3 | 22 |
| 165 | Estimating the effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil: a spatiotemporal modelling study. Lancet Infectious Diseases, The, 2022, 22, 1587-1595. | 9.1 | 24 |
| 166 | Reconstructing long-term dengue virus immunity in French Polynesia. PLoS Neglected Tropical Diseases, 2022, 16, e0010367. | 3.0 | 1 |
| 167 | Identifying Recent Cholera Infections Using a Multiplex Bead Serological Assay. MBio, 2022, 13, . | 4.1 | 4 |
| 168 | Temporal patterns of functional anti-dengue antibodies in dengue infected individuals with different disease outcome or infection history. Scientific Reports, 2022, 12, . | 3.3 | 1 |
| 170 | Considering waning immunity to better explain dengue dynamics. Epidemics, 2022, 41, 100630. | 3.0 | 3 |
| 172 | Biologics for dengue prevention: up-to-date. Expert Opinion on Biological Therapy, 0, , 1-15. | 3.1 | 3 |
| 174 | Dynamics of Anti-influenza Mucosal IgA Over a Season in a Cohort of Individuals Living or Working in a Long-term Care Facility. Journal of Infectious Diseases, 0, , . | 4.0 | 0 |
| 177 | Serum biomarkers and anti-flavivirus antibodies at presentation as indicators of severe dengue. PLoS Neglected Tropical Diseases, 2023, 17, e0010750. | 3.0 | 3 |
| 178 | A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. Nature Communications, 2023, 14, . | 12.8 | 9 |
| 179 | Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?. PLoS Pathogens, 2023, 19, e1011223. | 4.7 | 7 |
| 182 | Is new dengue vaccine efficacy data a relief or cause for concern?. Npj Vaccines, 2023, 8, . | 6.0 | 27 |
| 183 | Applying a multi-strain dengue model to epidemics data. Mathematical Biosciences, 2023, 360, 109013. | 1.9 | 4 |
| 185 | Resurgence of Omicron BA.2 in SARS-CoV-2 infection-naive Hong Kong. Nature Communications, 2023, 14, . | 12.8 | 8 |
| 186 | Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody. Microbiology Spectrum, 2023, 11, . | 3.0 | 1 |
| 187 | Insights into dengue immunity from vaccine trials. Science Translational Medicine, 2023, 15, . | 12.4 | 2 |
| 188 | A stochastic B cell affinity maturation model to characterize mechanisms of protection for tetravalent dengue vaccine constructs. Frontiers in Molecular Biosciences, 0, 10, . | 3.5 | 0 |

ARTICLE IF CITATIONS Dengue virus serotype 2 genotype III evolution during the 2019 outbreak in Mato Grosso, Midwestern 190 2.3 1 Brazil. Infection, Génetics and Évolution, 2023, 113, 105487. serosim: An R package for simulating serological data arising from vaccination, epidemiological and antibody kinetics processes. PLoS Computational Biology, 2023, 19, e1011384. 3.2 DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent 192 4.7 1 enhancement of DENV infection. PLoS Pathogens, 2023, 19, e1011616. Flaviviruses: Dengue., 2023, , 1-65. Maternally derived antibody titer dynamics and risk of hospitalized infant dengue disease. Proceedings 194 7.1 1 of the National Academy of Sciences of the United States of America, 2023, 120, . Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against 4.7 flaviviruses. PLoS Pathogens, 2023, 19, e1011722. Dengue Vaccination: Towards a New Dawn of Curbing Dengue Infection. Immunological Investigations, 196 2.0 0 2023, 52, 1096-1149. Effects of boosting and waning in highly exposed populations on dengue epidemic dynamics. Science Translational Medicine, 2023, 15, . 12.4 Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination. 198 11.0 1 Cell Host and Microbe, 2023, 31, 1850-1865.e5. Antibodyâ€mediated <scp>SARSâ€CoV</scp>â€2 entry in cultured cells. EMBO Reports, 2023, 24, . 4.5 Comparing the Performance of Three Models Incorporating Weather Data to Forecast Dengue 202 4.01 Epidemics in Reunion Island, 2018–2019. Journal of Infectious Diseases, 0, , . Flying under the radar – impact and factors influencing asymptomatic DENV infections. Frontiers in Céllular and Infection Microbiology, 0, 13, . Integrated control strategies for dengue, Zika, and Chikungunya virus infections. Frontiers in 204 4.8 0 Immunology, 0, 14, . Household immunity and individual risk of infection with dengue virus in a prospective, longitudinal 13.3 cohort study. Nature Microbiology, 0, , . Protection against symptomatic dengue infection by neutralizing antibodies varies by infection 207 12.8 0 history and infecting serotype. Nature Communications, 2024, 15, . Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice. 209 Nature Communications, 2024, 15, . Is a therapeutic dengue monoclonal antibody on the way?. Lancet Infectious Diseases, The, 2024, , . 212 9.1 0